March 2026 Research Update

This month, the new treatment information came from single-patient reports, so it cannot tell us what will happen for most people with CRMO. What it does add is a clearer picture that some patients need treatment escalation after a long diagnostic and treatment journey, and that different immune pathways may matter in different people. Across the cases, symptom control and imaging improvement were reported after changes to stronger immune-targeting medicines, but the evidence stays early because each report describes only one patient. [1] [2]

In one pediatric CNO case that affected only the clavicle, the patient had persistent symptoms despite several earlier steps, and later moved to pamidronate (a bone-strengthening infusion used in some inflammatory bone conditions) plus adalimumab (a TNF-blocking medicine). After this escalation, the report described sustained remission with pain and swelling resolving, inflammatory markers returning to normal, and stability on follow-up imaging for about 3 years. This example shows how treatment plans in CNO/CRMO may change over time when inflammation does not settle with earlier approaches, but it does not prove the same results would occur for others. [1]

A second case involved CRMO occurring alongside Takayasu arteritis and very early-onset ulcerative colitis, with CRMO developing despite ongoing infliximab (another TNF-blocking medicine). The report described remission of all three conditions after switching to tocilizumab (an IL-6 blocking medicine), with improved labs and imaging over a 6-month follow-up and no serious side effects reported in that period. This case adds an early signal that, in some complex inflammatory situations, changing which immune signal is targeted may coincide with better control, but longer follow-up and larger studies would be needed to know how often this applies. [2]

For patients and caregivers, these reports mainly add understanding rather than changing what is known with confidence. They show that CRMO/CNO can sometimes be part of a broader inflammatory picture, and that some individuals may only reach stable control after trying more than one type of immune-targeting medicine. What remains uncertain is how common these responses are, which patients are most likely to benefit from a specific medicine, and how durable the responses are beyond the limited follow-up in one of the cases. For now, this information is best viewed as early, real-world examples of what has been tried in challenging situations. [1] [2]

This month included an expert imaging document that aims to make evaluation of anterior chest wall inflammation more consistent across rheumatic conditions, including chronic nonbacterial osteitis (a related term often used alongside CRMO/CNO). The main message is a practical division of roles between tests: ultrasound first, MRI when active inflammation needs to be seen clearly, and CT when detailed bone structure or crystal disease questions are central. While this is not a results study, it reflects a push toward clearer imaging pathways and shared reporting language so that findings are easier to compare over time. [3]

The recommendations also emphasize using imaging to separate inflammatory chest wall disease from other possible explanations and to describe findings in a standardized way. In plain terms, this is about choosing the right scan for the question being asked, such as whether there is active inflammation in bone and nearby tissues versus whether the concern is fine bony detail. For someone living with CRMO/CNO, this kind of guidance may matter most when symptoms involve the front of the chest, because it tries to reduce uncertainty about which imaging tool is likely to be most informative. [3]

For patients, this work may matter now in the sense that it supports a more predictable approach to imaging choices when chest wall symptoms are part of the picture. It does not report that one imaging plan leads to better health outcomes, and it does not replace individualized decision-making. What it helps clarify is why different scans can be used at different times: ultrasound is often used first, MRI is often used to show active inflammation, and CT is often used when detailed bone information is needed. What remains uncertain is how much these recommendations change day-to-day care in different clinics, since access and local practice can vary. [3]